Related Experiment Video

Updated: May 13, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Pharmacological management of obese child

Razia Petkar1, Neil Wright

  • 1Department of Paediatric Endocrinology & Diabetes, Sheffield Children’s Hospital, Sheffield, UK.

Archives of Disease in Childhood. Education and Practice Edition
|March 12, 2013
PubMed

Insights

Childhood obesity is a growing concern. This review examines current and future drug treatments for pediatric obesity, emphasizing lifestyle interventions and clinical guidance.

Area of Science:

  • Pediatric Endocrinology
  • Clinical Pharmacology

Background:

  • Childhood overweight and obesity present significant clinical challenges.
  • Increasing prevalence necessitates effective management strategies.

Purpose of the Study:

  • To review the pharmacological management of pediatric obesity.
  • To discuss current and potential future therapeutic options.
  • To explore the role of lifestyle interventions and clinical guidance.

Main Methods:

  • Literature review of historical and current treatments.
  • Analysis of available pharmacological options (orlistat, metformin).
  • Discussion of evidence and clinical guidelines.

Main Results:

  • Orlistat and metformin are current pharmacological options.
  • Psychological and long-term health impacts of obesity are significant.
  • Integration of lifestyle interventions is crucial.

Conclusions:

  • Pharmacological interventions for pediatric obesity require careful consideration.
  • Evidence-based clinical guidance is essential for appropriate use.
  • Future research may yield novel therapeutic approaches.

Keywords:
ObesityPaediatric PracticePharmacologyTherapeutics

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...